Arenson M S, Evans S C
Section of Molecular Pharmacology, Division of Biomedical Sciences, School of Medicine and Dentistry, Queen Mary and Westfield College, University of London, Mile End Road, London E1 4NS, UK.
Neuroscience. 2001;104(4):1157-64. doi: 10.1016/s0306-4522(01)00114-2.
The effects of the dihydropyridine Ca(2+) channel antagonist nimodipine and the protein kinase C inhibitors staurosporine and calphostin C on the changes in the electrophysiological indices of quantal acetylcholine release induced by a 4-beta-phorbol ester were studied at the frog neuromuscular junction. 4-beta-Phorbol 12-myristate 13-acetate (200 nM) caused an increase in the frequency of miniature endplate potentials and miniature endplate currents and in the quantal content of endplate potentials and endplate currents. These effects were not replicated by 4-alpha-phorbol 12,13-didecanoate (200 nM). Nimodipine (1 microM) itself had no effect on the frequency of miniature endplate potentials and miniature endplate currents and it had no effect on the quantal content. Nimodipine inhibited by 83-98% the increase in these parameters induced by 4-beta-phorbol 12-myristate 13-acetate. The increase in the frequency of miniature endplate potentials and currents caused by KCl (12 mM) matched the increase caused by 20 min exposure to 4-beta-phorbol 12-myristate 13-acetate. Nimodipine did not reduce the increase in frequency caused by KCl. Unlike 4-beta-phorbol 12-myristate 13-acetate, KCl (12 mM) prevented neuromuscular transmission. The effects of prior exposure of muscles to staurosporine (5 microM) on 4-beta-phorbol 12-myristate 13-acetate-induced increases in quantal acetylcholine release were inconsistent. In some pretreated fibres, 4-beta-phorbol 12-myristate 13-acetate caused increases in miniature endplate potential frequency and quantal content which were as great as the largest values encountered in fibres that had not been pretreated. In others, 4-beta-phorbol 12-myristate 13-acetate did not have a marked effect; the frequency of the spontaneous potentials and the quantal content of endplate potentials recorded in the presence of 4-beta-phorbol 12-myristate 13-acetate were sometimes less than their respective control values. Pretreatment with calphostin C (500 nM) was more consistent; it prevented by 93-100% the 4-beta-phorbol 12-myristate 13-acetate-induced increases in the frequency of miniature endplate potentials and quantal content.Overall, from these results we suggest that activation of protein kinase C increases quantal acetylcholine release by opening quiescent L-type Ca(2+) channels in motor nerve terminals at resting potential and apparently not by depolarisation.
在青蛙神经肌肉接头处,研究了二氢吡啶类钙离子通道拮抗剂尼莫地平以及蛋白激酶C抑制剂星形孢菌素和钙磷蛋白C对4-β-佛波醇酯诱导的量子化乙酰胆碱释放电生理指标变化的影响。4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯(200 nM)导致微小终板电位和微小终板电流的频率增加,以及终板电位和终板电流的量子含量增加。4-α-佛波醇12,13-十二烷酸酯(200 nM)未复制这些效应。尼莫地平(1 μM)本身对微小终板电位和微小终板电流的频率没有影响,对量子含量也没有影响。尼莫地平可抑制4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯诱导的这些参数增加的83% - 98%。氯化钾(12 mM)引起的微小终板电位和电流频率增加与20分钟暴露于4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯引起的增加相匹配。尼莫地平并未降低氯化钾引起的频率增加。与4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯不同,氯化钾(12 mM)可阻断神经肌肉传递。预先将肌肉暴露于星形孢菌素(5 μM)对4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯诱导的量子化乙酰胆碱释放增加的影响并不一致。在一些预处理的纤维中,4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯引起的微小终板电位频率和量子含量增加与未预处理纤维中遇到的最大值一样大。在其他纤维中,4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯没有显著影响;在4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯存在下记录的自发电位频率和终板电位的量子含量有时低于其各自的对照值。用钙磷蛋白C(500 nM)预处理更具一致性;它可抑制4-β-佛波醇12-肉豆蔻酸酯13-乙酸酯诱导的微小终板电位频率和量子含量增加的93% - 100%。总体而言,从这些结果我们认为,蛋白激酶C的激活通过在静息电位下打开运动神经末梢中静止的L型钙离子通道来增加量子化乙酰胆碱释放,显然不是通过去极化。